TherapeuticsMD Inc (NASDAQ:TXMD) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 69,651,906 shares, an increase of 4.4% from the October 15th total of 66,719,902 shares. Based on an average daily volume of 3,686,691 shares, the short-interest ratio is presently 18.9 days. Currently, 36.5% of the company’s shares are sold short.
Several research firms have recently weighed in on TXMD. ValuEngine upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 21st. Oppenheimer set a $14.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, September 26th. Cantor Fitzgerald set a $27.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a report on Thursday, September 27th. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, August 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $13.45.
TherapeuticsMD stock opened at $4.93 on Friday. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $1.09 billion, a P/E ratio of -13.32 and a beta of 1.40. TherapeuticsMD has a one year low of $4.30 and a one year high of $7.66.
In other news, Director Brian Bernick sold 91,400 shares of the business’s stock in a transaction dated Friday, October 5th. The stock was sold at an average price of $5.93, for a total transaction of $542,002.00. Following the sale, the director now directly owns 242,000 shares in the company, valued at $1,435,060. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert G. Finizio sold 184,000 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $6.24, for a total value of $1,148,160.00. Following the sale, the chief executive officer now owns 18,485,559 shares in the company, valued at $115,349,888.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,158,800 shares of company stock worth $12,946,562. Company insiders own 22.85% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in shares of TherapeuticsMD by 10.6% in the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock worth $105,421,000 after acquiring an additional 1,537,045 shares during the period. FMR LLC lifted its stake in TherapeuticsMD by 14.7% in the third quarter. FMR LLC now owns 12,049,988 shares of the company’s stock valued at $79,048,000 after buying an additional 1,542,987 shares during the period. Voya Investment Management LLC lifted its stake in TherapeuticsMD by 7.7% in the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after buying an additional 242,995 shares during the period. Northern Trust Corp lifted its stake in TherapeuticsMD by 4.0% in the second quarter. Northern Trust Corp now owns 2,086,552 shares of the company’s stock valued at $13,021,000 after buying an additional 81,062 shares during the period. Finally, OppenheimerFunds Inc. lifted its stake in TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after buying an additional 286,123 shares during the period. 66.20% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Short Interest in TherapeuticsMD Inc (TXMD) Increases By 4.4%” was reported by WKRB News and is the property of of WKRB News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.wkrb13.com/2018/11/10/short-interest-in-therapeuticsmd-inc-txmd-increases-by-4-4.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.